



# Changes in the neurochemistry of athletes with repetitive brain trauma: preliminary results using localized correlated spectroscopy

## Citation

Lin, Alexander P, Saadallah Ramadan, Robert A Stern, Hayden C Box, Christopher J Nowinski, Brian D Ross, and Carolyn E Mountford. 2015. "Changes in the neurochemistry of athletes with repetitive brain trauma: preliminary results using localized correlated spectroscopy." *Alzheimer's Research & Therapy* 7 (1): 13. doi:10.1186/s13195-015-0094-5. <http://dx.doi.org/10.1186/s13195-015-0094-5>.

## Published Version

doi:10.1186/s13195-015-0094-5

## Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:14351267>

## Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

## Share Your Story

The Harvard community has made this article openly available. Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

RESEARCH

Open Access

# Changes in the neurochemistry of athletes with repetitive brain trauma: preliminary results using localized correlated spectroscopy

Alexander P Lin<sup>1\*</sup>, Saadallah Ramadan<sup>1,2</sup>, Robert A Stern<sup>3,4</sup>, Hayden C Box<sup>1</sup>, Christopher J Nowinski<sup>3,6</sup>, Brian D Ross<sup>1,5</sup> and Carolyn E Mountford<sup>1,2</sup>

## Abstract

**Introduction:** The goal was to identify which neurochemicals differ in professional athletes with repetitive brain trauma (RBT) when compared to healthy controls using a relatively new technology, *in vivo* Localized COrelated Spectroscopy (L-COSY).

**Methods:** To achieve this, L-COSY was used to examine five former professional male athletes with 11 to 28 years of exposure to contact sports. Each athlete who had had multiple symptomatic concussions and repetitive subconcussive trauma during their career was assessed by an experienced neuropsychologist. All athletes had clinical symptoms including headaches, memory loss, confusion, impaired judgment, impulse control problems, aggression, and depression. Five healthy men, age and weight matched to the athlete cohort and with no history of brain trauma, were recruited as controls. Data were collected from the posterior cingulate gyrus using a 3 T clinical magnetic resonance scanner equipped with a 32 channel head coil.

**Results:** The variation of the method was calculated by repeated examination of a healthy control and phantom and found to be 10% and 5%, respectively, or less. The L-COSY measured large and statistically significant differences ( $P \leq 0.05$ ), between healthy controls and those athletes with RBT. Men with RBT showed higher levels of glutamine/glutamate (31%), choline (65%), fucosylated molecules (60%) and phenylalanine (46%). The results were evaluated and the sample size of five found to achieve a significance level  $P = 0.05$  and a power of 90%. Differences in N-acetyl aspartate and myo-inositol between RBT and controls were small and were not statistically significant.

**Conclusions:** A study of a small cohort of professional athletes, with a history of RBT and symptoms of chronic traumatic encephalopathy when compared with healthy controls using 2D L-COSY, showed elevations in brain glutamate/glutamine and choline as recorded previously for early traumatic brain injury. For the first time increases in phenylalanine and fucose are recorded in the brains of athletes with RBT. Larger studies utilizing the L-COSY method may offer an in-life method of diagnosis and personalized approach for monitoring the acute effects of mild traumatic brain injury and the chronic effects of RBT.

## Introduction

There is increasing recognition of long-term neurological difficulties from head injuries, especially from repetitive concussive and sub-concussive brain trauma. Chronic traumatic encephalopathy (CTE) is a progressive neurodegenerative disease, found post mortem, in individuals with

histories of repetitive brain trauma (RBT), such as contact sport athletes and combat military personnel [1]. Early symptoms of RBT include impaired memory and executive functioning. Mood disturbance, including depression, apathy, suicidal tendencies and behavior change, follow as do impulsivity and aggression [1]. Later in the disease course, dementia can develop as well as motor disturbance in some people [2]. Autopsy studies have revealed a distinct pattern of neuropathological changes known as CTE which includes: tau-immunoreactive proteins in the cerebral cortex; neurofibrillary and glial tangles; generalized

\* Correspondence: [aplin@partners.org](mailto:aplin@partners.org)

<sup>1</sup>Center for Clinical Spectroscopy, Department of Radiology, Brigham & Women's Hospital, Harvard Medical School, 4 Blackfan Street HIM-820, Boston, MA 02115, USA

Full list of author information is available at the end of the article

atrophy; enlarged ventricles; degeneration of white matter fiber bundles; cavum septum pellucidum; and a relative absence of beta-amyloid (A $\beta$ ) deposits [3,4].

The neuropathological diagnosis of CTE is well documented but there is a need for an *in vivo* diagnosis to provide an in life and personalized approach to manage this disease. An in life test will also facilitate research into the risk factors, epidemiology, prevention and treatment. Magnetic resonance spectroscopy (MRS) can be used to noninvasively record neurochemical changes as a result of RBT. One-dimensional MRS allows neurochemicals, mobile on the MR timescale, to be monitored noninvasively in a clinical MR scanner [5]. However, many of these neurochemicals overlap in the one-dimensional MR spectrum making it difficult to determine the precise level of change to each chemical population. A single chemical species can be measured at one time using MR spectral editing techniques [6-8] but these do not allow comparison of how the neurochemicals alter in relation to one another [9,10].

The introduction of Localized (L) COrelated Spectroscopy (L-COSY) overcame this issue [11,12]. L-COSY utilizes a simple three-pulse sequence:

$$90_{\phi_1}-180_{\phi_2}-t_1-90_{\phi_3}-\text{Acq}_{\phi_4}(\phi \text{ is phase})$$

whereby each row in the final spectrum is acquired in succession and  $t_1$  time delay is incremented by a set value, thereby providing a two-dimensional spectrum. In an L-COSY spectrum, a 'cross peak' off the diagonal indicates scalar coupling between the two protons it connects on the diagonal, thus providing chemical specificity not available to conventional one-dimensional MRS. Using data collected in a whole body commercially available scanner at 3 T, there are many more molecules now open for inspection in the brain using the L-COSY method with higher certainty. This L-COSY method has been applied successfully to other organs including muscle and bone marrow [13] and brain [11]. The advantage of L-COSY is that it allows for unambiguous identification and measurement of metabolites, lipids and macromolecules, compared to the one-dimensional MR spectra [14]. For the brain, the L-COSY allows over 35 different resonances to be inspected, each of which can be related to function, disease or injury [11].

The L-COSY protocol, using the 32 channel head coil, was previously reported to be effective for studying the human brain with a signal to noise ratio sufficient to monitor the neurochemicals from healthy brain and glioma [11]. The spectral quality allowed similar chemical information, recorded from cultured cells at 8.4 T, to be seen *in vivo* from the brain of patients with glioblastoma in a 3 T clinical scanner. In the glioma study, the changes to neurochemistry were large. Much smaller

changes were anticipated from subjects with RBT. Here, we report the results of a pilot study, using the L-COSY method, on chronic sports-induced repetitive head injury in elite athletes compared with healthy age-matched controls with no history of head injury. Although the cohort is small, we report large differences in neurochemistry, with statistical significance, not previously described for RBT.

## Methods

### Magnetic resonance

#### Hardware

Data were acquired on a 70 cm wide bore Siemens Verio (Siemens AG, Erlangen, Germany) using the operating software VB17 using the 32 channel head coil (Siemens AG).

#### MRI and MRS protocol

Prior to the spectroscopy data collection, routine brain magnetic resonance imaging (MRI) was performed with axial 3D-MPRAGE and reconstructed in the sagittal and coronal planes with 2 mm slice resolution for accurate localization of the voxel. The posterior cingulate gyrus (PCG), predominantly comprising gray matter, was chosen for examination as it had been reported to be sensitive to traumatic brain injury [15,16]. Furthermore, post mortem CTE studies show deposition of tau protein in the cortical gray matter areas including the cingulate [3].

The L-COSY protocol was undertaken as described in Ramadan *et al.* [11] with a 32 channel head coil, using 64 increments with 8 averages, and a repetition time (TR) of 1.5 seconds resulting in an acquisition time of 12.8 minutes. The data were acquired from a voxel in the PCG (size  $3 \times 3 \times 3 \text{ cm}^3$ ), acquired vector size 1,024 points; acquisition time 512 ms; spectral width in F2 2,000 Hz and spectral width in F1 1,250 Hz (0.8 ms increment size).

Localized shimming was undertaken by adjustment of zero- and first-order shim gradients using the automatic B0 field mapping technique supplied by the vendor (Siemens AG) followed by manual adjustment of zero-order shim gradients to achieve a resulting peak width of water at half-maximum that was 14 Hz or less. Following frequency adjustment, water-selective suppression was achieved using the WET-technique [17] programmed into the pulse sequence.

### Subjects

The study was approved by the local institutional review boards (Partners Human Research Committee and Boston University Medical Campus Institutional Review Board) and was compliant with the Health Insurance Portability and Accountability Act. All subjects provided informed consent and consent for publication.

Five retired professional male athletes participated in the study ( $43.6 \pm 10.8$  years) (Table 1). They had 11 to

**Table 1 Description of RBT cohort**

| Case | Age group | Sport                 | Professional years | Total years | Cognitive and neuropsychiatric symptom severity |
|------|-----------|-----------------------|--------------------|-------------|---|
| A    | 30 to 35  | Football/Wrestling    | 3                  | 11          | +   |
| B    | 30 to 35  | Football              | 7                  | 28          | ++  |
| C    | 30 to 35  | Baseball <sup>a</sup> | 7                  | 11          | ++  |
| D    | 40 to 55  | Football              | 9                  | 21          | ++  |
| E    | 40 to 55  | Football              | 7                  | 16          | +++   |

<sup>a</sup>In addition to baseball-related concussions, subject also had several concussions from non-sports-related activities. +mild cognitive and neuropsychiatric symptoms; ++moderate cognitive and neuropsychiatric symptoms; +++significant cognitive and neuropsychiatric symptoms. RBT, repetitive brain trauma.

28 years ( $17.4 \pm 7.2$  years) of exposure to repetitive brain trauma in contact sports, including American football ( $n = 3$ ), professional wrestling ( $n = 1$ ) and baseball ( $n = 1$ ). Each athlete had experienced multiple symptomatic concussions (including several concussions with loss of consciousness) as well as repetitive sub-concussive trauma during his career. The subjects were all examined at the chronic stage of injury 3 to 25 ( $13.8 \pm 10.1$ ) years since the end of their careers and had no recently reported head injuries. Subjects were each evaluated by an experienced neuropsychologist (RAS) within a few days of MR examination via a personal interview; a semi quantitative neuropsychological test score was assigned to each (see Table 1). All five former athletes had reported clinical symptoms associated with either prolonged post-concussive syndrome or early CTE, including headaches, memory loss, confusion, impaired judgment, impulse control problems, aggression and depression [2]. Five healthy men, who were not professional athletes, were recruited as control subjects. They were age and weight matched to the athletes ( $45.2 \pm 12.6$  years; no significant difference from subjects), with no history of brain trauma.

To determine the variation of each cross peak using this L-COSY sequence, data were accrued four times in succession from phantom solutions of the major metabolites (N-acetyl aspartate, creatine, choline and myo-inositol) at physiological concentrations and pH as well as five times in succession in a volunteer (man, age 42). The coefficient of variation of each cross peak was calculated.

#### Data processing

Raw L-COSY data were transferred to MATLAB [18] for signal combination from multiple elements followed by row concatenation into a two-dimensional matrix. Commercial two-dimensional spectral processing software (Felix-2007, Accelrys, San Diego, CA, USA) was used for observer-independent spectral processing and analysis.

The processing parameters used were: F2 domain (skewed sine-squared window, 2,048 points, magnitude mode), F1 domain (sine-squared window, linear prediction to 96 points, zero-filling to 512 points, magnitude mode). The effect of altering time domains and window functions in two-dimensional COSY has been documented elsewhere [19]. Residual water was removed by using a Felix built-in Gaussian shaped convolution-based method. The total creatine methyl diagonal resonance at 3.02 ppm was used as an internal chemical shift reference in F1 and F2. All 'cross' or off-diagonal peaks are denoted with F2 – F1 in ppm units. When preparing the spectra for figures, each spectrum was calibrated by setting the lysine cross peak (at 3.00– 1.67 ppm) and specifying a constant 'number of contour levels' (set to 28), as well as a constant 'level multiplier' (defined as the difference between values of consecutive contour, set to 1.05). The volumes of cross peaks or diagonal resonances were evaluated using Felix software described above, and care was taken to ensure that the interrogated volume was the same in all L-COSY spectra. To further avoid operator bias, this was done by creating a fixed template to analyze the L-COSY data. All identifiable peaks according to Govindaraju [20], Lean [21] or Ramadan [11] were reported and peaks were measured and normalized to the creatine diagonal peak volume at 3.02 ppm for comparable results across all scans. The post processing that was ultimately chosen for the study was the same as for the glioma study [11].

#### Statistical analysis

Wilcoxon ranked sum tests were performed to determine statistical significance. Bonferroni correction was not used due to the small sample size, the large number of independent variables and the pilot nature of this study. A significance level of 0.05 was utilized to compare data from the RBT cohort and healthy controls. Altman's Nomogram [22], determined by the size of the differences was employed to determine the minimum sample size for  $P \leq 0.05$  at a level of 90% significance for future studies.

## Results

#### Variation of the L-COSY method

The *in vivo* coefficients of variation are summarized in Table 2 where the internal reference creatine had a variation of 1% while the other metabolites were 10% or less. In the phantom solutions, a variation of 5% or less was obtained.

The mean cross peak area of lysine (Lys, at 3.00– 1.67 ppm) referenced to creatine was found to be the same in both RBT subjects and controls. Therefore, Lys was used to set the same contour levels across all data sets for presentation.



**Table 2 Reproducibility of the L-COSY method: single healthy volunteer over five separate scans**

| Molecule              | Coupling   | F2-F1 (ppm)                | Variation (%) |
|-----------------------|--|----------------------------|---------------|
| Cr                    | N(CH <sub>3</sub> )  | 3.02–3.02                  | 1             |
| Glx-1                 | -CH <sub>2</sub> -CH(NH <sub>3</sub> <sup>+</sup> )                        | 2.09–3.75                  | 4             |
| Glx-3                 |  | 2.07–3.73                  | 4             |
| Glx-4                 |  | 2.14–3.74                  | 5             |
| Glx-6                 |  | 2.45–2.01                  | 6             |
| Glx-7                 |  | 2.31–2.28                  | 6             |
| tCho                  | (CH <sub>3</sub> ) <sub>3</sub> -N + -CH <sub>2</sub> -CH <sub>2</sub> -OH | 4.05–4.05                  | 2             |
| Fucose region and Thr | <b>-CH(OH)-CH<sub>3</sub></b> CH <sub>3</sub> -CH                          | (F2: 4.0–4.5, F1: 1.1–1.7) | 10            |
| Phe                   | <b>-CH</b> (aromatic)-   | 7.33–7.33                  | 7             |
| NAA                   | <b>-CH<sub>3</sub></b>   | 2.00–2.00                  | 2             |
| Cho                   | (CH <sub>3</sub> ) <sub>3</sub> -N + -CH <sub>2</sub> -CH <sub>2</sub> -OH | 3.51–4.05                  | 3             |
|                       | <b>(CH<sub>3</sub>)<sub>3</sub>-N + -CH<sub>2</sub>-CH<sub>2</sub>-OH</b>  | 3.20–3.20                  | 5             |
| ml                    | <b>-CH(OH)-CH(OH)</b>  | 3.63–3.29                  | 5             |
|                       |  | 3.55–3.55                  | 3             |

Abbreviations: Cho, choline; Cr, creatine; Glx 1-7, crosspeaks of glutamate + glutamine; L-COSY, localized correlated spectroscopy; ml, myo-inositol; NAA, N-acetyl aspartate; Phe, phenylalanine; ppm, parts per million; Thr, threonine. In bold are the proton groups that give rise to the crosspeak chemical shifts indicated in the third column.

### Healthy versus repetitive brain trauma


Importantly, none of the athletes recorded structural MRI abnormalities using conventional imaging metrics. A typical L-COSY spectrum from a healthy male with no history of brain trauma is shown in Figure 1A. This is compared to L-COSY data recorded from a professional male athlete of similar age and weight, with history of

RBT, and with cognitive symptoms in Figure 1B. These representative spectra demonstrate well-resolved cross and diagonal peaks including amino acids: alanine, aspartate, isoleucine, leucine, lysine, taurine, threonine (Thr), phenylalanine (Phe); membrane phospholipids: glycerophosphorylcholine, phosphocholine, phosphoethanolamine; neurotransmitters:  $\gamma$ -amino-butyric acid (GABA), glutamate/glutamine (Glx); major metabolites: N-acetyl aspartate (NAA), choline (Cho), creatine (Cr), myo-inositol (ml), glutathione (GSH), taurine, lactate, multiple lipid resonances, and macromolecules.

Large and significant differences in neurochemical levels were recorded when comparing age-matched RBT subjects to controls using non-parametric tests ( $P \leq 0.05$ ). Summarized in Table 3 and Figure 2 (scatterplot) are those cross peaks which are significantly different. Additional metabolites of interest such as NAA and ml (both have been shown to change in other traumatic brain injury (TBI) studies [23,24]) where changes were small or not statistically significant in this pilot series are also shown (Table 4).

The RBT cohort recorded an increase of 31%, 32% and 35% in the glutamine/glutamate cross peaks (2.09–3.75 ppm, 2.07–3.73 ppm and 2.14–3.74 ppm, respectively) (Table 3) when compared to controls. Figure 2 clearly demonstrates that for most of the Glx resonances there is no overlap between the RBT and control cohorts. It remains contentious as to whether glutamate and glutamine resonances are separable; thus, it cannot yet be ascertained if the increase is in glutamine or glutamate or both.

The methylene group of choline at 4.05–4.05 ppm was 65% higher in the RBT cohort. The scatterplot (Figure 2) shows that there is no overlap between the cross peak values measured in RBT subjects and controls. It is



**Figure 1 L-COSY spectra. A)** Age-matched healthy control; **B)** Athlete with history of RBT. Spectroscopy was performed at 3 T using a 32 channel head coil and voxel size of  $3 \times 3 \times 3 \text{ cm}^3$  in the PCG; increment size 0.8 ms; 64 increments with 8 averages resulting in an acquisition time of 12.8 minutes; acquired vector 1,024 points; acquisition time 512 ms; spectral width in F2 2,000 Hz and spectral width in F1 1,250 Hz. Assigned neurochemicals are according to Ramadan *et al.* [11] and Lean [21]. For presentation, the spectra were calibrated to the lysine cross peak at 3.00–1.67 ppm. Abbreviations: N-acetylaspartate (NAA), choline (Cho); creatine (Cr); glutamate (Glu) and glutamine together (Glx); aspartate (Asp); myo-inositol (ml); lysine (Lys); threonine (Thr), gamma-aminobutyric acid (GABA). L-COSY, localized correlated spectroscopy; PCG, posterior cingulate gyrus; RBT, repetitive brain trauma.

**Table 3 Statistically significant differences between healthy and RBT subjects**

| Molecule              | Coupling                  | F2-F1 (ppm)                | Control mean volume/Cr | RBT mean volume/Cr | % Diff between mean and RBT | Effect size |
|-----------------------|---------------------------|----------------------------|------------------------|--------------------|-----------------------------|-------------|
| Glx-1                 | -CH2- CH(NH3+)            | 2.09-3.75                  | 0.112 ± 0.009          | 0.147 ± 0.017      | 31 ± 18                     | 3.11        |
| Glx-3                 |                           | 2.07-3.73                  | 0.022 ± 0.002          | 0.029 ± 0.004      | 32 ± 21                     | 2.70        |
| Glx-4                 |                           | 2.14-3.74                  | 0.031 ± 0.002          | 0.042 ± 0.007      | 35 ± 24                     | 2.88        |
| Glx-6                 |                           | 2.45-2.01                  | 0.018 ± 0.001          | 0.041 ± 0.011      | 77 ± 6                      | 6.28        |
| tCho                  | (CH3)3-N + -CH2-CH2-OH    | 4.05-4.05                  | 0.250 ± 0.071          | 0.413 ± 0.051      | 65 ± 36                     | 3.54        |
| Fucose region and Thr | <b>-CH(OH)-CH3</b> CH3-CH | (F2: 4.0-4.5, F1: 1.1-1.7) | 0.022 ± 0.007          | 0.036 ± 0.011      | 64 ± 61                     | 2.64        |
| Phe                   | -CH-(aromatic)-           | 7.33-7.33                  | 0.024 ± 0.005          | 0.035 ± 0.008      | 46 ± 40                     | 2.08        |


Cross peak volumes were calculated relative to creatine. % Diff is the difference of the control and RBT means divided by the control mean ± the standard deviation. In bold are the proton groups that give rise to the crosspeak chemical shifts indicated in the third column.

Abbreviations: Glx, crosspeaks of glutamate + glutamine; Phe, phenylalanine; RBT, repetitive brain trauma; tCho, total choline; Thr, threonine.

interesting to note that while the mean peak volumes of the choline resonances at 3.20-3.20 ppm and 3.51-4.05 ppm were greater, they were not statistically significant.

L-COSY also uniquely identifies additional resonances that cannot be characterized by one-dimensional MRS methods. For example, the cross peaks in the F2: 4.0-4.5, F1: 1.1-1.7 region, show a higher cross peak volume in molecules assigned to covalently linked terminal fucose molecules and threonine [21] of 60% in the RBT

group [21]. The spectral region (F2: 4.0-4.5, F1: 1.1-1.7) contains threonine, fucose and, sometimes, lactate cross peaks. Originally assigned in the two-dimensional COSY from cultured cells [21,25] and more recently *in vivo* in the brain [11], these fucose cross peaks are also seen in the brain spectra reported by Velan *et al.* [14], but assigned to Thr/lactate alone. The assignment of bound fucose in the two-dimensional MR spectra was previously made using *in vitro* models by treating the cultured cells



**Table 4 Additional metabolites of interest**

| Molecule | Coupling                             | F2-F1 (ppm) | Control mean volume/Cr | RBT mean volume/Cr | % Diff between mean and RBT | Effect size |
|----------|--------------------------------------|-------------|------------------------|--------------------|-----------------------------|-------------|
| NAA      | <b>-CH3</b>                          | 2.00–2.00   | 1.215 ± 0.101          | 1.294 ± 0.070      | 7 ± 10                      | 0.95        |
| tCho     | (CH3)3-N + <b>-CH2-CH2-OH</b>        | 3.51–4.05   | 0.018 ± 0.002          | 0.020 ± 0.016      | 11 ± 81                     | 0.23        |
|          | <b>(CH3)3-N</b> + <b>-CH2-CH2-OH</b> | 3.20–3.20   | 0.726 ± 0.009          | 0.774 ± 0.052      | 7 ± 7                       | 1.63        |
| ml       | <b>-CH(OH)-CH(OH)</b>                | 3.63–3.29   | 0.029 ± 0.013          | 0.032 ± 0.011      | 10 ± 61                     | 0.26        |
|          |                                      | 3.55–3.55   | 0.342 ± 0.013          | 0.354 ± 0.029      | 4 ± 10                      | 0.58        |

Data are presented as described in Table 3, that is, relative to creatine. In all cases, the differences between control and RBT were not statistically significant. Abbreviations: ml, myo-inositol; NAA, N-acetyl aspartate; RBT, repetitive brain trauma; tCho, total choline. In bold are the proton groups that give rise to the crosspeak chemical shifts indicated in the third column.

with fucosyl transferase and observing the bound cross peaks disappear and free  $\alpha$  fucose at 1.22–4.21 ppm and free  $\beta$  fucose at 1.26–3.81 ppm appear [25]. It is the unique conformation of each of these terminal fucosylated species on the oligosaccharide chain on the cell membrane that generates the different chemical shifts for each fucose. Replicating this in a phantom is, thus, not possible [26].

An expansion of the aromatic region (F2: 6.00–9.00 ppm; F1: 6.00–9.00 ppm) where resonances [20] from phenylalanine (Phe; 7.33–7.33 ppm); imidazole from histamine and homocarnosine (Imi; 7.07–7.07 ppm); and high-frequency peak from NAA amine group and imidazole from histamine and histidine (HF; 7.82–7.82 ppm) on the diagonal are shown in Figure 3 as expanded from Figure 1. Phenylalanine was 46% higher in RBT subjects compared with controls and statistically significant.


Based on the literature, two other molecules expected to increase with RBT were NAA and myo-inositol (Table 4). They were increased by 7% and 10%, respectively; however, these changes were relatively small and they did not reach statistical significance [22]. This is of particular interest given that these metabolites have been shown to

be significantly altered in other studies of head injury but do not appear to be different in this limited cohort.

## Discussion

### Neurochemical changes with chronic repetitive brain trauma

This study demonstrates that the L-COSY method documents neurochemical differences in former professional athletes with a history of RBT compared to healthy age-matched controls with no history of head injury. Changes in cerebral metabolites after severe TBI, in both children and adults, have shown strong correlations with clinical grade and patient outcome in previous studies [16,27,28]. The changes expected from previous one-dimensional MRS of sports-related TBI's [9,10,29] included changes in NAA, choline and glutamine in acute and sub-acute stages of injury. However, this is the first study to examine the chronic changes in athletes with a history of RBT and the first to apply two-dimensional L-COSY methodology. An important outcome from this study is the ability to monitor a larger range of molecules with greater accuracy. For example, large increases in glutamine/glutamate, choline and phenylalanine are evident and molecules such as the



**Figure 3** An expansion of the aromatic region (F2: 6.00–9.00 ppm; F1: 6.00–9.00 ppm). Resonances from phenylalanine (Phe; 7.33–7.33); imidazole from histamine and homocarnosine (Imi; 7.07–7.07); and high-frequency peak from NAA amine group and imidazole from histamine and histidine (HF; 7.82–7.82) are on the diagonal. The data are again expanded from Figure 1. On the left are the results from the healthy control and on the right from the athletes with RBT, in which phenylalanine cross peaks are well visualized. There is a mean statistically significant greater phenylalanine by 46% in the RBT group as a whole. NAA, N-acetyl aspartate; RBT, repetitive brain trauma.

fucosylated glycans are now available for inspection in the brain *in vivo*. While the changes observed in this cohort are not necessarily representative of the heterogeneous population of athletes with RBT, these preliminary results may provide new insights into the biochemical pathways being altered as a function of RBT.

The composite glutamate/glutamine was over 30% higher in the athletes with RBT. Glutamate is a major excitatory neurotransmitter and neuronal biomarker, the increase in which is known to be predictive of poor outcome in severe TBI [30]. Glutamine, the second metabolite contributing to the region designated Glx, is a predominantly glial metabolite and may, therefore, provide information relevant to the gliosis or neuroinflammation identified in other studies of Alzheimer disease (AD) [31] and hepatitis [32]. TBI alters the brain homeostasis resulting in the activation of microglia via proinflammatory cytokines [33] and in mouse models of CTE, repetitive brain injury resulted in augmentation of tau pathology as well as glial activation [34]. Recently, resting and activated glial density was shown to be increased in subjects with CTE when compared with controls, and those with CTE and motor neuron disease showed even greater glial density [35]. Another link to CTE can be found in the clinical features of CTE. Recent work has shown, through next-of-kin interviews of 36 athletes all with neuropathologically confirmed CTE, a distinct initial clinical presentation at a younger age of behavioral and mood disturbances and initial presentation at an older age that involved cognitive impairment [36]. Several studies have shown that changes in glutamate occur in depression and other mood disorders [37,38].

Choline was 65% higher in RBT subjects. Importantly, there was no overlap between the choline values of each group, thereby demonstrating a distinct difference between the RBT and control groups. Previous studies have demonstrated that increased total choline which includes several related membrane metabolites (phosphocholine, glycerophosphocholine, phosphoethanolamine, glycerophosphoethanolamine, and so on) is reflective of brain tissue damage or diffuse axonal injury in TBI [39]. It is unclear at this time if the unambiguous choline measured by COSY is part of the same mechanism but the large difference in this small cohort bears further study.

The cross peaks assigned to fucosylated glycans at (F1 0.90–1.70; F24.0–4.50) increased by 60% in subjects with RBT. The levels of fucosylated epitopes, for example, sialyl Lewis x, have been shown to increase during the early events of inflammation [40–43]. Others have shown that fucosylation of glycoproteins increases in inflammation which may be related to the inflammation shown in chronic brain injury by positron emission tomography (PET) studies [44]. In the healthy brain fucose- $\alpha$ (1–2)-galactose (Fuca(1–2)Gal) sugars have been implicated in

the molecular mechanisms that underlie neuronal development, learning and memory [26]).

Phenylalanine, increased by 46% in the brains of the RBT cohort, can be converted into tyrosine - another of the DNA-encoded amino acids. Tyrosine, in turn, is converted into 3,4-dihydroxyphenylalanine (Dopa), which is further converted into dopamine, noradrenalin and adrenaline [45]. This elevation may well be the result of interference with a critical part of the noradrenergic and adrenergic neurotransmitter pathways after RBT. Phenylalanine in increased quantities also interferes with the production of serotonin, an imbalance of which is thought to influence mood in a way that leads to depression [46].

Finally, mI was not found to be significantly different in RBT subjects. Previous studies have shown that brain trauma is a risk factor for dementia [47,48] which has led some to believe that the underlying cause for dementia following TBI may be CTE and not AD in itself [49,50]. Although CTE is neuropathologically distinct from AD [4], the same study also showed that 11% of the American football players had co-morbid AD. Furthermore, the differential diagnosis of these two diseases in life is difficult if not possible based solely on clinical presentation. Just as in AD, initial symptoms of CTE can include impaired episodic memory and in late stage CTE dementia can be clinically mistaken for AD [2]. As a result, the relationship between TBI and neurodegenerative disease, such as AD, will remain unclear until a two-dimensional L-COSY study is undertaken on AD and a larger RBT cohort.

#### Study limitations and future studies

A major limitation to this study is the small sample size. The goal of this pilot investigation was to establish initial data on the utility of L-COSY MRS in distinguishing individuals with a history of RBT from healthy controls. It is not possible to determine if the changes observed in this small sample of former athletes with histories of RBT are indicative of the progressive neurodegenerative disease CTE or are a reflection of the residual, chronic effects of the initial brain injuries. Furthermore, head injury is heterogeneous and, thus, a larger sample may have a greater variability that is not reflected in this small cohort. Additional studies are planned to focus on this and other important issues with the goal of utilizing L-COSY MRS as a biomarker for CTE.

The capacity to measure changes in this larger number of neurochemicals at one time, with high accuracy, and on a personalized basis, is now possible using the L-COSY technique. Such an approach could alter long term care of the patients with RBT and other neurological diseases. Much interest lies in clarification as to whether the data presented here are the result of persistent, chronic post-concussion syndrome and/or the neurodegenerative disease identified post mortem as CTE. This question will



not be answered quickly as individuals need to be followed over time. However, of more immediate use is the L-COSY method to assist with a multi-modal biomarker diagnostic approach to CTE, leading to the ability to examine risk factors and prevalence of this neurodegenerative disease, as well as to understand better the prevention and treatment of RBT.

## Conclusions

This study demonstrates that two-dimensional L-COSY can document neurochemical changes in former professional athletes who have experienced RBT and symptoms including headaches, memory loss, confusion, impaired judgment, impulse control problems, aggression and depression. Large and significant increases in the neurochemicals glutamate/glutamine and choline are recorded as expected from earlier studies but phenylalanine and fucosylated molecules have not been recorded previously in RBT or mTBI. The literature links these four neurochemicals to glutamatergic neurotoxicity, diffuse axonal injury, neurotransmitter dysfunction and neuro inflammation. These results need to be confirmed by future studies with a larger cohort that may provide the basis for developing in life diagnosis of CTE. For smaller differences recorded, the appropriate group sizes were calculated to guide future study sizes.

## Abbreviations

AD: Alzheimer's disease; Asp: aspartate; A $\beta$ : beta-amyloid; Cho: choline; COSY: correlated spectroscopy; Cr: creatine; CTE: chronic traumatic encephalopathy; CV: coefficient of variation; Dop $\alpha$ : 3,4-dihydroxyphenylalanine; Fuc: fucosylated Protein; GABA: gamma-aminobutyric acid; Glu: glutamate; Glx: glutamate and glutamine; HF: high-frequency peak (from NAA amine group); Imi: imidazole; L-COSY: localized correlated spectroscopy; Lys: lysine; ml: myoinositol; MRS: magnetic resonance spectroscopy; mTBI: mild traumatic brain injury; NAA: N-acetylaspartate; PCG: posterior cingulate gyrus; PET: positron emission tomography; RBT: repetitive brain trauma; TBI: traumatic brain injury; Thr: threonine; TR: repetition time.

## Competing interests

APL, SR, RAS and CM are co-inventors of a patent entitled 'Magnetic Resonance Spectroscopy Provides a Non Invasive Means of Monitoring Repetitive Head Injury (USPTO, ed. A61B5/055 ed. USA: Brigham and Women's Hospital, 2011; US2011/062211). All other authors declare that they have no competing interests.

## Authors' contributions

APL contributed to the conception and design of the study, acquisition of MRS data, two-dimensional COSY data analysis and interpretation of data, drafted the manuscript and revised it critically for important intellectual content. SR contributed to the two-dimensional COSY data analysis, interpretation of data, drafted the manuscript and revised the manuscript critically for important intellectual content. RAS contributed to the conception and design of the study, subject recruitment, neuropsychological evaluation, interpretation of the data, drafted the manuscript and revised it critically for important intellectual content. HCB contributed to the two-dimensional COSY data analysis and drafted the manuscript. CJN contributed to the conception and design of the study, subject recruitment and revised the manuscript critically for important intellectual content. BDR contributed to the statistical analysis, interpretation of the data, drafting of the manuscript and revised it critically for important intellectual content. CEM contributed to the conception and design of the study, two-dimensional COSY data analysis and interpretation of the data, drafted the manuscript and revised it critically for important intellectual content. All authors read and approved the final manuscript.

## Acknowledgements

This research was conducted with the support of a grant from a pilot grant from Harvard Catalyst, The Harvard Clinical and Translational Science Center; NIH Grant #1 UL1 RR 025758-02; and financial contributions from participating institutions as well as the Department of Defense Congressionally Directed Medical Research Programs in Psychological Health/Traumatic Brain Injury (W81XWH-10-1-0835). Early aspects of this work were supported by the Australian Research Council (DP0663987). Additional support for the BU Center for the Study of Traumatic Encephalopathy has been received from the National Operating Committee on Standards for Athletic Equipment, as well as NIH Grants P30-AG13846 and R01-NS078337, and an unrestricted gift was received from the USA National Football League.

## Author details

<sup>1</sup>Center for Clinical Spectroscopy, Department of Radiology, Brigham & Women's Hospital, Harvard Medical School, 4 Blackfan Street HIM-820, Boston, MA 02115, USA. <sup>2</sup>Centre for MR in Health, School of Health Sciences, University of Newcastle, Newcastle, NSW 2308, Australia. <sup>3</sup>Center for the Study of Traumatic Encephalopathy, Boston University School of Medicine, Boston, MA 02118, USA. <sup>4</sup>BU Alzheimer's Disease Center, Boston University School of Medicine, Boston, MA 02118, USA. <sup>5</sup>Clinical Spectroscopy, Huntington Medical Research Institutes, Pasadena, CA 91105, USA. <sup>6</sup>Sports Legacy Institute, Waltham, MA 02451, USA.

Received: 16 August 2013 Accepted: 7 January 2015

Published online: 15 March 2015

## References

- Gavett BE, Cantu RC, Shenton M, Lin AP, Nowinski CJ, McKee AC, et al. Clinical appraisal of chronic traumatic encephalopathy: current perspectives and future directions. *Curr Opin Neurol*. 2011;24:525-31.
- Stern RA, Daneshvar DH, Baugh CM, Seichepine DR, Montenigro PH, Riley DO, et al. Clinical presentation of chronic traumatic encephalopathy. *Neurology*. 2013;81:1122-9.
- McKee A, Cantu R, Nowinski C, Hedley-Whyte E, Gavett B, Budson A, et al. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. *J Neuropathol Exp Neurol*. 2009;68:709-35.
- McKee AC, Stern RA, Nowinski CJ, Stein TD, Alvarez VE, Lee HS, et al. The spectrum of disease in chronic traumatic encephalopathy. *Brain*. 2012;136:43-64.
- Mountford CE, Stanwell P, Lin A, Ramadan S, Ross B. Neurospectroscopy: the past, present and future. *Chem Rev*. 2010;110:3060-86.
- Jansen JF, Backes WH, Nicolay K, Kooi ME. H-1 MR spectroscopy of the brain: absolute quantification of metabolites. *Radiology*. 2006;240:318-32.
- Kaiser LG, Marjanska M, Matson GB, Iltis I, Bush SD, Soher BJ, et al. 1H MRS detection of glycine residue of reduced glutathione in vivo. *J Magn Reson B*. 2010;202:259-66.
- Snyder J, Wilman A. Field strength dependence of PRESS timings for simultaneous detection of glutamate and glutamine from 1.5 to 7 T. *J Magn Reson B*. 2010;203:66-72.
- Henry LC, Tremblay S, Boulanger Y, Ellemberg D, Lassonde M. Neurometabolic changes in the acute phase after sports concussions correlate with symptom severity. *J Neurotrauma*. 2010;27:65-76.
- Vagnozzi R, Signoretti S, Cristofori L, Alessandrini F, Floris R, Isgrò E, et al. Assessment of metabolic brain damage and recovery following mild traumatic brain injury: a multicentre, proton magnetic resonance spectroscopic study in concussed patients. *Brain*. 2010;133:3232-42.
- Ramadan S, Andronesi O, Stanwell P, Lin A, Sorenson G, Mountford C. In vivo two dimensional MR spectroscopy compares the biochemistry of the human brain and glioblastoma. *Radiology*. 2011;259:540-9.
- Thomas M, Yue K, Binesh N, Davanzo P, Kumar A, Siegel B, et al. Localized two-dimensional shift correlated MR spectroscopy of human brain. *Magn Reson Med*. 2001;46:58-67.
- Ramadan S, Mountford CE, Mulkern R. w-3 fatty acid detection by L-COSY in human bone marrow at 3T [abstract]. In: *Proceedings of the International Society of Magnetic Resonance in Medicine*. 2010. Stockholm, Sweden: Wiley; 2010. p. 1478.
- Velan SS, Lemieux SK, Raylman RR, Boling W, Hobbs GR, Spencer RG, et al. Detection of cerebral metabolites by single-voxel-based PRESS and COSY techniques at 3 T. *J Magn Reson Imaging*. 2007;26:405-9.

15. Ashwal S, Holshouser BA, Shu SK, Simmons PL, Perkin RM, Tomasi LG, et al. Predictive value of proton magnetic resonance spectroscopy in pediatric closed head injury. *Pediatr Neurol*. 2000;23:114–25.
16. Ross BD, Ernst T, Kreis R, Haseler LJ, Bayer S, Danielsen E, et al. 1H MRS in acute traumatic brain injury. *J Magn Reson Imaging*. 1998;8:829–40.
17. Ogg R, Kingsley P, Taylor J. WET, a T1- and B1-insensitive water-suppression method for in vivo localized 1H NMR spectroscopy. *J Magn Reson B*. 1994;104:1–10.
18. MATLAB and Statistics Toolbox Release 7.01.24704(R14). The MathWorks, Inc., Natick, Massachusetts, US.
19. Delikatny EJ, Hull WE, Mountford CE. The effect of altering time domains and window functions in two-dimensional proton COSY spectra of biological specimens. *J Magn Reson*. 1991;94:463–73.
20. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. *NMR Biomed*. 2000;13:129–53.
21. Lean CL, Mackinnon WB, Delikatny EJ, Whitehead RH, Mountford CE. Cell-surface fucosylation and magnetic resonance spectroscopy characterization of human malignant colorectal cells. *Biochemistry*. 1992;31:11095–105.
22. Altman DG. Statistical reviewing for medical journals. *Stat Med*. 1998;17:2661–74.
23. Kierans AS, Kirov II, Gonen O, Haemer G, Nisenbaum E, Babb JS, et al. Myoinositol and glutamate complex neurometabolite abnormality after mild traumatic brain injury. *Neurology*. 2014;82:521–8.
24. Kirov II, Tal A, Babb JS, Reaume J, Bushnik T, Ashman TA, et al. Proton MR spectroscopy correlates diffuse axonal abnormalities with post-concussive symptoms in mild traumatic brain injury. *J Neurotrauma*. 2013;30:1200–4.
25. Lean CL, Mackinnon WB, Mountford CE. Fucose in 1H COSY spectra of plasma membrane fragments shed from human malignant colorectal cells. *Magn Reson Med*. 1991;20:306–11.
26. Murrey HE, Ficarro SB, Krishnamurthy C, Domino SE, Peters EC, Hsieh-Wilson LC. Identification of the plasticity-relevant fucose- $\alpha$ (1–2)-galactose proteome from the mouse olfactory bulb. *Biochemistry*. 2009;48:7261–70.
27. Brooks WM, Stidley CA, Petropoulos H, Jung RE, Weers DC, Friedman SD, et al. Metabolic and cognitive response to human traumatic brain injury: a quantitative proton magnetic resonance study. *J Neurotrauma*. 2000;17:629–40.
28. Shutter L, Tong KA, Holshouser BA. Proton MRS in acute traumatic brain injury: role for glutamate/glutamine and choline for outcome prediction. *J Neurotrauma*. 2004;21:1693–705.
29. Lin AP, Liao HJ, Merugumala SK, Prabhu SP, Meehan 3rd WP, Ross BD. Metabolic imaging of mild traumatic brain injury. *Brain Imaging Behav*. 2012;6:208–23.
30. Chamoun R, Suki D, Gopinath SP, Goodman JC, Robertson C. Role of extracellular glutamate measured by cerebral microdialysis in severe traumatic brain injury. *J Neurosurg*. 2010;113:564–70.
31. Lee M. Neurotransmitters and microglial-mediated neuroinflammation. *Curr Protein Pept Sci*. 2013;14:21–32.
32. Nagarajan RS, Thames AD, Castellon SA, Hinkin CH, Thomas MA. 2D MR spectroscopy combined with prior-knowledge fitting is sensitive to HCV-associated cerebral metabolic abnormalities. *Int J Hepatol*. 2012;2012:179365.
33. Kumar A, Loane DJ. Neuroinflammation after traumatic brain injury: opportunities for therapeutic intervention. *Brain Behav Immun*. 2012;26:1191–201.
34. Ojo JO, Mouzon B, Greenberg MB, Bachmeier C, Mullan M, Crawford F. Repetitive mild traumatic brain injury augments tau pathology and glial activation in aged hTau mice. *J Neuropathol Exp Neurol*. 2013;72:137–51.
35. Ferrerola L, Stein TD, McKee AC. Increased neuroinflammation in chronic traumatic encephalopathy. Boston, MA: In: BUSM Medical Student Summer Research Symposium; 2013. <http://www.bumc.bu.edu/enrichment/files/2013/01/ferrerola-lauren.pdf>.
36. Stern RA, Daneshvar DH, Baugh CM, Seichepine DR, Montenigro PH, Riley DO, et al. Clinical presentation and ApoE genotype of neuropathologically confirmed chronic traumatic encephalopathy in athletes. *Neurology*. 2013;81:1122–9.
37. Yuksel C, Ongur D. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. *Biol Psychiatry*. 2010;68:785–94.
38. Valentine GW, Sanacora G. Targeting glial physiology and glutamate cycling in the treatment of depression. *Biochem Pharmacol*. 2009;78:431–9.
39. Holshouser BA, Tong KA, Ashwal S. Proton MR spectroscopic imaging depicts diffuse axonal injury in children with traumatic brain injury. *AJNR Am J Neuroradiol*. 2005;26:1276–85.
40. De Graaf TW, der Stelt V, Anbergen MG, van Dijk W. Inflammation-induced expression of sialyl Lewis X-containing glycan structures on alpha 1-acid glycoprotein (orosomucoid) in human sera. *J Experimental Med*. 1993;177:657–66.
41. Smalla KH, Angenstein F, Richter K, Gundelfinger ED, Staak S. Identification of fucose- $\alpha$ [1–2]-galactose epitope-containing glycoproteins from rat hippocampus. *Neuroreport*. 1998;9:813–7.
42. Hoeche N, Kaehne T, Kobler O, Richter K, Tischmeyer W, Dieterich DC, et al. Mapping fucosylated synaptic proteins. Amsterdam: In: FENS Forum 2010; 2010. p. 105.7. [http://fens2010.neurosciences.asso.fr/abstracts/r4/a105\\_7.html](http://fens2010.neurosciences.asso.fr/abstracts/r4/a105_7.html).
43. Lowe JB. Glycan-dependent leukocyte adhesion and recruitment in inflammation. *Curr Opin Cell Biol*. 2003;15:531–8.
44. Ramackhansingh AF, Brooks DJ, Greenwood RJ, Bose SK, Turkheimer FE, Kinnunen KM, et al. Inflammation after trauma: microglial activation and traumatic brain injury. *Ann Neurol*. 2011;70:374–83.
45. Bagchi SP, Smith TM. Dopamine formation from phenylalanine: independent existence in caudate nucleus synaptosomes. *J Neural Transm*. 1977;41:101–7.
46. Sharman R, Sullivan K, Young RM, McGill J. Depressive symptoms in adolescents with early and continuously treated phenylketonuria: associations with phenylalanine and tyrosine levels. *Gene*. 2012;504:288–91.
47. Plassman BL, Havlik RJ, Steffens DC, Helms MJ, Newman TN, Drosdick D, et al. Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. *Neurology*. 2000;55:1158–66.
48. Schofield PW, Tang M, Marder K, Bell K, Dooneief G, Chun M, et al. Alzheimer's disease after remote head injury: an incidence study. *J Neurol Neurosurg Psychiatry*. 1997;62:119–24.
49. Lehman EJ, Hein MJ, Baron SL, Gersic CM. Neurodegenerative causes of death among retired national football league players. *Neurology*. 2012;79:1970–4.
50. Shively S, Scher AI, Perl DP, Diaz-Arrastia R. Dementia resulting from traumatic brain injury: what is the pathology? *Arch Neurol*. 2012;69:1245–51.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

